Search research articles
Contact Us
Filters
Showing results (81-90 of 97) with videos related to
Page
of 10
Sort By:
Breast Cancer Research : BCR
|
October 29, 2022
Tolerability of Eribulin and correlation between polymorphisms and neuropathy in an unselected population of female patients with metastatic breast cancer: results of the multicenter, single arm, phase IV PAINTER study
Nicla La Verde, Giovanna Damia, Ornella Garrone, et al.
Journal of Cellular Physiology
|
July 16, 2017
Neoadjuvant chemotherapy in triple-negative breast cancer: A multicentric retrospective observational study in real-life setting
Teresa Gamucci, Laura Pizzuti, Isabella Sperduti, et al.
Journal of Cellular Physiology
|
November 19, 2016
A Real-World Multicentre Retrospective Study of Paclitaxel-Bevacizumab and Maintenance Therapy as First-Line for HER2-Negative Metastatic Breast Cancer
Teresa Gamucci, Lucia Mentuccia, Clara Natoli, et al.
The Oncologist
|
August 14, 2014
Real-world study of everolimus in advanced progressive neuroendocrine tumors
Francesco Panzuto, Maria Rinzivillo, Nicola Fazio, et al.
Journal of the National Cancer Institute
|
April 19, 2007
Adjuvant treatment of high-risk, radically resected gastric cancer patients with 5-fluorouracil, leucovorin, cisplatin, and epidoxorubicin in a randomized controlled trial
Stefano Cascinu, Roberto Labianca, Carlo Barone, et al.
Cancer Biology & Therapy
|
January 17, 2018
Body mass index in HER2-negative metastatic breast cancer treated with first-line paclitaxel and bevacizumab
Laura Pizzuti, Domenico Sergi, Isabella Sperduti, et al.
Oncotarget
|
February 25, 2016
"Triple positive" early breast cancer: an observational multicenter retrospective analysis of outcome
Patrizia Vici, Laura Pizzuti, Isabella Sperduti, et al.
Cancer Biology & Therapy
|
November 8, 2018
A multicenter REtrospective observational study of first-line treatment with PERtuzumab, trastuzumab and taxanes for advanced HER2 positive breast cancer patients. RePer Study
Teresa Gamucci, Laura Pizzuti, Clara Natoli, et al.
Oncotarget
|
September 17, 2017
A retrospective multicentric observational study of trastuzumab emtansine in HER2 positive metastatic breast cancer: a real-world experience
Patrizia Vici, Laura Pizzuti, Andrea Michelotti, et al.
Journal of Experimental & Clinical Cancer Research : CR
|
December 11, 2020
Loss of HER2 and decreased T-DM1 efficacy in HER2 positive advanced breast cancer treated with dual HER2 blockade: the SePHER Study
Giulia Bon, Laura Pizzuti, Valentina Laquintana, et al.
Page
of 10
Search research articles
Search
Showing results (81-90 of 97) with videos related to
Sort By:
Page
of 10
Breast Cancer Research : BCR
|
October 29, 2022
Tolerability of Eribulin and correlation between polymorphisms and neuropathy in an unselected population of female patients with metastatic breast cancer: results of the multicenter, single arm, phase IV PAINTER study
Nicla La Verde, Giovanna Damia, Ornella Garrone, et al.
Journal of Cellular Physiology
|
July 16, 2017
Neoadjuvant chemotherapy in triple-negative breast cancer: A multicentric retrospective observational study in real-life setting
Teresa Gamucci, Laura Pizzuti, Isabella Sperduti, et al.
Journal of Cellular Physiology
|
November 19, 2016
A Real-World Multicentre Retrospective Study of Paclitaxel-Bevacizumab and Maintenance Therapy as First-Line for HER2-Negative Metastatic Breast Cancer
Teresa Gamucci, Lucia Mentuccia, Clara Natoli, et al.
The Oncologist
|
August 14, 2014
Real-world study of everolimus in advanced progressive neuroendocrine tumors
Francesco Panzuto, Maria Rinzivillo, Nicola Fazio, et al.
Journal of the National Cancer Institute
|
April 19, 2007
Adjuvant treatment of high-risk, radically resected gastric cancer patients with 5-fluorouracil, leucovorin, cisplatin, and epidoxorubicin in a randomized controlled trial
Stefano Cascinu, Roberto Labianca, Carlo Barone, et al.
Cancer Biology & Therapy
|
January 17, 2018
Body mass index in HER2-negative metastatic breast cancer treated with first-line paclitaxel and bevacizumab
Laura Pizzuti, Domenico Sergi, Isabella Sperduti, et al.
Oncotarget
|
February 25, 2016
"Triple positive" early breast cancer: an observational multicenter retrospective analysis of outcome
Patrizia Vici, Laura Pizzuti, Isabella Sperduti, et al.
Cancer Biology & Therapy
|
November 8, 2018
A multicenter REtrospective observational study of first-line treatment with PERtuzumab, trastuzumab and taxanes for advanced HER2 positive breast cancer patients. RePer Study
Teresa Gamucci, Laura Pizzuti, Clara Natoli, et al.
Oncotarget
|
September 17, 2017
A retrospective multicentric observational study of trastuzumab emtansine in HER2 positive metastatic breast cancer: a real-world experience
Patrizia Vici, Laura Pizzuti, Andrea Michelotti, et al.
Journal of Experimental & Clinical Cancer Research : CR
|
December 11, 2020
Loss of HER2 and decreased T-DM1 efficacy in HER2 positive advanced breast cancer treated with dual HER2 blockade: the SePHER Study
Giulia Bon, Laura Pizzuti, Valentina Laquintana, et al.
Page
of 10